CA2598517A1 - Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease - Google Patents

Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease Download PDF

Info

Publication number
CA2598517A1
CA2598517A1 CA002598517A CA2598517A CA2598517A1 CA 2598517 A1 CA2598517 A1 CA 2598517A1 CA 002598517 A CA002598517 A CA 002598517A CA 2598517 A CA2598517 A CA 2598517A CA 2598517 A1 CA2598517 A1 CA 2598517A1
Authority
CA
Canada
Prior art keywords
compound
effective amount
pharmaceutically effective
pharmaceutically acceptable
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002598517A
Other languages
English (en)
French (fr)
Inventor
John Ernest Doe
Nicholas Crispinian Sturgess
Kim Zachary Travis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2598517A1 publication Critical patent/CA2598517A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
CA002598517A 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease Abandoned CA2598517A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0504103.3 2005-02-28
GBGB0504103.3A GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method
PCT/GB2006/000684 WO2006090177A1 (en) 2005-02-28 2006-02-27 USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE

Publications (1)

Publication Number Publication Date
CA2598517A1 true CA2598517A1 (en) 2006-08-31

Family

ID=34430351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002598517A Abandoned CA2598517A1 (en) 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease

Country Status (17)

Country Link
US (1) US20090326072A1 (enExample)
EP (1) EP1853241B1 (enExample)
JP (1) JP2008531665A (enExample)
CN (1) CN101163466B (enExample)
AT (1) ATE524171T1 (enExample)
AU (1) AU2006217650B2 (enExample)
BR (1) BRPI0609177A2 (enExample)
CA (1) CA2598517A1 (enExample)
DK (1) DK1853241T3 (enExample)
ES (1) ES2374761T3 (enExample)
GB (1) GB0504103D0 (enExample)
IL (1) IL185410A0 (enExample)
MX (1) MX2007010480A (enExample)
PT (1) PT1853241E (enExample)
RU (1) RU2420272C2 (enExample)
WO (1) WO2006090177A1 (enExample)
ZA (1) ZA200707486B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3311813B1 (en) 2007-08-27 2019-08-07 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US20100160295A1 (en) * 2008-11-06 2010-06-24 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
PL2723320T3 (pl) * 2011-06-23 2016-06-30 Swedish Orphan Biovitrum Int Ab Ciekła kompozycja farmaceutyczna zawierająca nityzynon
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
MA42519A (fr) * 2015-07-29 2018-06-06 Takeda Gmbh Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
US5092919A (en) * 1991-01-15 1992-03-03 Imperial Chemical Industries Plc Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones
DK0591275T3 (da) * 1991-06-24 1999-10-11 Zeneca Ltd Anvendelse af 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyklohexandion til behandling af tyrosinæmi samt farmaceutiske sammen
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20050288187A1 (en) * 2002-07-03 2005-12-29 Hanauske-Abel Hartmut M Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
EP1646377A4 (en) * 2003-07-11 2009-09-09 Merck & Co Inc TREATMENT OF MOVEMENT DISORDERS WITH METABOTROPIC GLUTAMATE 4 RECEPTOR POSITIVE ALLOSTERIC MODULATOR
AU2006347397A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of HPPD inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
US20100160295A1 (en) * 2008-11-06 2010-06-24 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders

Also Published As

Publication number Publication date
BRPI0609177A2 (pt) 2010-02-23
ES2374761T3 (es) 2012-02-21
AU2006217650A1 (en) 2006-08-31
IL185410A0 (en) 2008-08-07
MX2007010480A (es) 2008-02-07
EP1853241B1 (en) 2011-09-14
PT1853241E (pt) 2012-01-11
AU2006217650B2 (en) 2011-06-09
RU2420272C2 (ru) 2011-06-10
CN101163466A (zh) 2008-04-16
CN101163466B (zh) 2011-12-07
EP1853241A1 (en) 2007-11-14
JP2008531665A (ja) 2008-08-14
ZA200707486B (en) 2009-02-25
WO2006090177A1 (en) 2006-08-31
US20090326072A1 (en) 2009-12-31
DK1853241T3 (da) 2012-01-16
GB0504103D0 (en) 2005-04-06
HK1110211A1 (en) 2008-07-11
RU2007131934A (ru) 2009-02-27
ATE524171T1 (de) 2011-09-15

Similar Documents

Publication Publication Date Title
Bakun et al. In vitro and in vivo biological activities of azulene derivatives with potential applications in medicine
EP3444249B1 (en) Sodium channel blockers, preparation method thereof and use thereof
EA038531B1 (ru) Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб
EP1853241B1 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease
CN112274524A (zh) 人参二醇皂苷Rb组分在制备防治代谢紊乱相关疾病药物中的应用
WO2023122320A1 (en) Polypodal serotonergic compounds and prodrugs of serotonin receptor agonists and antagonists
JP2022544299A (ja) リモノイド化合物およびチアゾリジンジオン化合物を含有する組合せ製品
KR20080033456A (ko) 염증성 피부 상태의 치료를 위한 식물수 조성물
JP2018177739A (ja) Ｔｒｐａ１活性化剤
JP2016534055A (ja) オイゲノールを有効成分として含有するアトピー性皮膚炎の予防又は治療用組成物
US20180085345A1 (en) Methods of tracking skin conditions using cyclolignan compounds
WO2006041121A1 (ja) 慢性皮膚疾患の治療および／または予防剤
CA2659424A1 (en) Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
HK1110211B (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione in the treatment of parkinson's disease
KR102105533B1 (ko) 아마이드 유도체 화합물
JP2015512407A (ja) 動脈硬化性血管疾患を処置するための方法及び組成物
HK1142836A (en) Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
KR102251917B1 (ko) N-사이아노설폰아마이드를 유효성분으로 포함하는 관절염의 예방 또는 치료용 약학적 조성물
Williams et al. Xanthine Oxidase-Induced Vascular Dysfunction in Inhalation Toxicology: 163
KR20200105469A (ko) 푸니칼라진을 포함하는 소양증 예방, 개선 또는 치료용 조성물
HK1261581A1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131114